Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Akums Drugs & Pharmaceuticals was recently granted a patent for its breakthrough 'tablet in tablet' technology --- designed ...

bupropion hydrochloride is also made as a twice-daily sustained-release tablet (bupropion SR), as well as a once-daily extended-release tablet (known as bupropion XL). Wellbutrin is sold as ...

Tablet’ Technology Brings relief for expectant mothers: Our Bureau, Bengaluru Monday, May 5, 2025, 13:45 Hrs [IST] Akums Drugs & Pharmaceuticals, a ...

GSK markets controlled sustained-release tablets of bupropion hydrochloride as Wellbutrin SR for the treatment of depression and as Zyban for smoking cessation. The cases began when Impax ...

Akums receives DCGI approval and a patent for its dual-action, extended-release Doxylamine-Pyridoxine formulation for ...

Objective: To compare the 24-hour sustained efficacy and safety ... of Contramid ® permits the design of tablets that are tailored to release tramadol continuously over a 24-hour period.

The controlled-release oxycodone tablet formulation (OCRT) was approved in China in 2004 for management of moderate to severe cancer pain. Few data about the efficacy of OCRT and clinical outcomes ...